{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T05:38:37Z","timestamp":1768887517600,"version":"3.49.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1097\/ico.0b013e31815873c7","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T03:08:32Z","timestamp":1236222512000},"page":"50-55","source":"Crossref","is-referenced-by-count":48,"title":["Effects of Loteprednol\/Tobramycin Versus Dexamethasone\/Tobramycin on Intraocular Pressure in Healthy Volunteers"],"prefix":"10.1097","volume":"27","author":[{"given":"Edward J","family":"Holland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimmy D","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R","family":"Paterno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dale W","family":"Usner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy L","family":"Comstock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-8-20210204","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00002018-200225010-00004","article-title":"Locally administered ocular corticosteroids: benefits and risks.","volume":"25","author":"McGhee","year":"2002","journal-title":"Drug Saf"},{"key":"R2-8-20210204","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2165\/00148581-200406050-00003","article-title":"Treatment of ocular inflammation in children.","volume":"6","author":"Thadani","year":"2004","journal-title":"Paediatr Drugs"},{"key":"R3-8-20210204","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/00061198-199510000-00010","article-title":"Basic sciences in clinical glaucoma steroids, ocular hypertension, and glaucoma.","volume":"4","author":"Clark","year":"1995","journal-title":"J Glaucoma"},{"key":"R4-8-20210204","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/sj.eye.6701895","article-title":"Corticosteroid-induced glaucoma: a review of the literature.","volume":"20","author":"Kersey","year":"2006","journal-title":"Eye"},{"key":"R5-8-20210204","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2165\/00002512-199915060-00004","article-title":"Corticosteroids and glaucoma risk.","volume":"15","author":"Tripathi","year":"1999","journal-title":"Drugs Aging"},{"key":"R6-8-20210204","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1442-9071.2005.01022.x","article-title":"Ocular hypertensive and anti-inflammatory responses to different dosages of topical dexamethasone in children: a randomized trial.","volume":"33","author":"Lam","year":"2005","journal-title":"Clin Experiment Ophthalmol"},{"key":"R7-8-20210204","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/S0161-6420(00)00357-2","article-title":"Ocular hypertensive response to topical dexamethasone in children: a dose-dependent phenomenon.","volume":"107","author":"Ng","year":"2000","journal-title":"Ophthalmology"},{"key":"R8-8-20210204","first-page":"597","article-title":"3rd. New corticosteroids for the treatment of ocular inflammation.","volume":"127","author":"Whitcup","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"R9-8-20210204","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/02713689509033519","article-title":"Effectiveness of specific antibiotic\/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis.","volume":"14","author":"Engel","year":"1995","journal-title":"Curr Eye Res"},{"key":"R10-8-20210204","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0149-2918(04)80113-9","article-title":"Comparison of topical tobramycin-dexamethasone with dexamethasone-neomycin-polymyxin and neomycin-polymyxin-gramicidin for control of inflammation after cataract surgery: results of a multicenter, prospective, three-arm, randomized, double-masked, controlled, parallel-group study.","volume":"26","author":"Notivol","year":"2004","journal-title":"Clin Ther"},{"key":"R12-8-20210204","doi-asserted-by":"crossref","first-page":"E820","DOI":"10.1208\/aapsj070479","article-title":"Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems.","volume":"7","author":"Bodor","year":"2005","journal-title":"AAPS J"},{"key":"R13-8-20210204","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1089\/jop.1998.14.153","article-title":"Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite, pj-91, following chronic ocular administration.","volume":"14","author":"Howes","year":"1998","journal-title":"J Ocul Pharmacol Ther"},{"key":"R14-8-20210204","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1350-9462(98)00035-4","article-title":"Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma.","volume":"18","author":"Wordinger","year":"1999","journal-title":"Prog Retin Eye Res"},{"key":"R15-8-20210204","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/S0161-6420(98)99054-6","article-title":"A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The loteprednol etabonate postoperative inflammation study group 2.","volume":"105","year":"1998","journal-title":"Ophthalmology"},{"key":"R16-8-20210204","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/jop.1993.9.157","article-title":"Intraocular pressure response to loteprednol etabonate in known steroid responders.","volume":"9","author":"Bartlett","year":"1993","journal-title":"J Ocul Pharmacol"},{"key":"R17-8-20210204","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/02713689308999455","article-title":"Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis.","volume":"12","author":"Bartlett","year":"1993","journal-title":"Curr Eye Res"},{"key":"R18-8-20210204","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0002-9394(14)71128-6","article-title":"A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group.","volume":"123","author":"Dell","year":"1997","journal-title":"Am J Ophthalmol"},{"key":"R19-8-20210204","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00061198-199808000-00009","article-title":"Change in intraocular pressure during long-term use of loteprednol etabonate.","volume":"7","author":"Novack","year":"1998","journal-title":"J Glaucoma"},{"key":"R20-8-20210204","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0091-6749(98)70094-6","article-title":"A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis.","volume":"102","author":"Dell","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"R21-8-20210204","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.ICL.0000092071.82938.46","article-title":"Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis.","volume":"30","author":"Ilyas","year":"2004","journal-title":"Eye Contact Lens"},{"key":"R22-8-20210204","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0161-6420(99)90077-5","article-title":"A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis.","volume":"106","author":"Shulman","year":"1999","journal-title":"Ophthalmology"},{"key":"R23-8-20210204","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S0886-3350(98)80170-3","article-title":"Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1.","volume":"24","author":"Stewart","year":"1998","journal-title":"J Cataract Refract Surg"},{"key":"R24-8-20210204","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0002-9394(14)70171-0","article-title":"A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I.","volume":"123","author":"Friedlaender","year":"1997","journal-title":"Am J Ophthalmol"},{"key":"R25-8-20210204","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ajo.2004.04.052","article-title":"A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance.","volume":"138","author":"Pflugfelder","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R26-8-20210204","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0002-9394(99)00034-3","article-title":"Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group.","volume":"127","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"R27-8-20210204","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/0014-4835(85)90130-7","article-title":"Glucocorticoid-lens protein adducts in experimentally induced steroid cataracts.","volume":"40","author":"Bucala","year":"1985","journal-title":"Exp Eye Res"},{"key":"R28-8-20210204","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3109\/02713689109020329","article-title":"Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes.","volume":"10","author":"Druzgala","year":"1991","journal-title":"Curr Eye Res"},{"key":"R29-8-20210204","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1172\/JCI111599","article-title":"Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts.","volume":"74","author":"Manabe","year":"1984","journal-title":"J Clin Invest"},{"key":"R30-8-20210204","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/00061198-200404000-00003","article-title":"Risk factors for elevated intraocular pressure in uveitis.","volume":"13","author":"Herbert","year":"2004","journal-title":"J Glaucoma"},{"key":"R31-8-20210204","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0039-6257(97)00006-4","article-title":"Glaucoma associated with uveitis.","volume":"41","author":"Moorthy","year":"1997","journal-title":"Surv Ophthalmol"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00003226-200801000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:39:46Z","timestamp":1618277986000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003226-200801000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e31815873c7","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}